NSE BSE
glenmark pharmaceuticals stock

GLENMARK PHARMACEUTICALS Share Price

- - (%)
- NSE: GLENMARK

GLENMARK PHARMACEUTICALS Share Price Update

As of the latest trading session, GLENMARK PHARMACEUTICALS share price is currently at 1412.95, which is down by -0.40 from its previous closing. Today, the stock has fluctuated between 1383.10 and 1417.50. Over the past year, GLENMARK PHARMACEUTICALS has achieved a return of 96.21 %. In the last month alone, the return has been 14.34 %. Read More...

GLENMARK PHARMACEUTICALS Performance

Day Range

Low1383.10 High1417.50
1412.95

52 Week Range

Low 715.20 High 1427.00
1412.95

GLENMARK PHARMACEUTICALS Share Price

7406

532296

GLENMARK

img img img img
No Data Available

Open Price

1414.65

Prev. Close

1413.35

Volume (Shares)

747528.00

Total traded value

10562.19

Upper Circuit

1554.65

Lower Circuit

1272.05

Note: The current prices & values are delayed, Login to your account for live updates.

GLENMARK PHARMACEUTICALS Fundamentals


(Standalone)

Market Cap (Cr) 39868.95
PE Ratio (TTM) 7.72
Book Value / Share 814.01
Beta 0.86
ROE 9.12%
EPS (TTM) 50.49
Dividend Yield 0.18%
Net Profit Qtr (Cr) 4613.70

GLENMARK PHARMACEUTICALS Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 2077.13
Operating Expense 1786.57
Net Profit 4613.70
Net Profit Margin (%) 222.11
Earnings Per Share (EPS) 163.50
EBITDA 6430.64
Effective Tax Rate (%) 26.70
Particulars DEC 2023 (Values in Cr)
Revenue 1304.16
Operating Expense 1674.12
Net Profit -20.41
Net Profit Margin (%) -1.56
Earnings Per Share (EPS) -0.72
EBITDA 49.25
Effective Tax Rate (%) 72.96
Particulars SEP 2023 (Values in Cr)
Revenue 2170.40
Operating Expense 1897.96
Net Profit 302.35
Net Profit Margin (%) 13.93
Earnings Per Share (EPS) 10.72
EBITDA 497.41
Effective Tax Rate (%) 22.34
Particulars JUN 2023 (Values in Cr)
Revenue 2098.06
Operating Expense 1770.07
Net Profit 271.66
Net Profit Margin (%) 12.94
Earnings Per Share (EPS) 9.63
EBITDA 502.72
Effective Tax Rate (%) 30.70
Particulars MAR 2023 (Values in Cr)
Revenue 1874.97
Operating Expense 1826.96
Net Profit -137.47
Net Profit Margin (%) -7.33
Earnings Per Share (EPS) -4.87
EBITDA -207.73
Effective Tax Rate (%) 56.12
Particulars MAR 2024 (Values in Cr)
Revenue 7649.76
Operating Expense 7128.73
Net Profit 5167.29
Net Profit Margin (%) 67.54
Earnings Per Share (EPS) 183.13
EBITDA 7480.01
Effective Tax Rate (%) 26.18
Particulars MAR 2023 (Values in Cr)
Revenue 8019.67
Operating Expense 7138.86
Net Profit 1208.77
Net Profit Margin (%) 15.07
Earnings Per Share (EPS) 42.84
EBITDA 1962.84
Effective Tax Rate (%) 23.10
Particulars MAR 2022 (Values in Cr)
Revenue 8017.38
Operating Expense 6849.10
Net Profit 1997.79
Net Profit Margin (%) 24.91
Earnings Per Share (EPS) 70.80
EBITDA 2733.18
Effective Tax Rate (%) 14.53
Particulars MAR 2021 (Values in Cr)
Revenue 7450.91
Operating Expense 6094.30
Net Profit 1649.45
Net Profit Margin (%) 22.13
Earnings Per Share (EPS) 58.46
EBITDA 2360.48
Effective Tax Rate (%) 15.14
Particulars MAR 2020 (Values in Cr)
Revenue 6491.20
Operating Expense 5803.33
Net Profit 1354.55
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 48.00
EBITDA 1929.57
Effective Tax Rate (%) 11.73
Particulars MAR 2023 (Values in Cr)
Book Value / Share 335.75
ROE % 6.91
ROCE % 14.28
Total Debt to Total Equity 0.46
EBITDA Margin 19.93
Particulars MAR 2022 (Values in Cr)
Book Value / Share 322.03
ROE % 14.36
ROCE % 15.77
Total Debt to Total Equity 0.55
EBITDA Margin 20.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 250.37
ROE % 14.77
ROCE % 14.70
Total Debt to Total Equity 0.75
EBITDA Margin 19.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.14
ROE % 13.29
ROCE % 13.70
Total Debt to Total Equity 0.80
EBITDA Margin 17.77
Particulars MAR 2019 (Values in Cr)
Book Value / Share 198.65
ROE % 15.20
ROCE % 14.71
Total Debt to Total Equity 0.84
EBITDA Margin 18.18
Particulars MAR 2023 (Values in Cr)
Book Value / Share 633.57
ROE % 9.12
ROCE % 10.79
Total Debt to Total Equity 0.20
EBITDA Margin 29.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 593.21
ROE % 10.42
ROCE % 10.93
Total Debt to Total Equity 0.24
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 524.84
ROE % 11.77
ROCE % 12.39
Total Debt to Total Equity 0.26
EBITDA Margin 31.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 468.73
ROE % 10.76
ROCE % 11.13
Total Debt to Total Equity 0.27
EBITDA Margin 28.75
Particulars MAR 2019 (Values in Cr)
Book Value / Share 423.22
ROE % 12.04
ROCE % 12.83
Total Debt to Total Equity 0.27
EBITDA Margin 30.72
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1469.69
Total Assets 19371.67
Total Liabilities 19371.67
Total Equity 9839.25
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 1.53
Return on Capital (%) 2.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1411.51
Total Assets 17083.28
Total Liabilities 17083.28
Total Equity 9438.12
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 5.51
Return on Capital (%) 7.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1139.15
Total Assets 15603.57
Total Liabilities 15603.57
Total Equity 7064.27
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 6.21
Return on Capital (%) 8.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1111.24
Total Assets 14684.80
Total Liabilities 14684.80
Total Equity 6070.11
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 5.28
Return on Capital (%) 7.35
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 937.76
Total Assets 13295.64
Total Liabilities 13295.64
Total Equity 5604.80
Share Outstanding 282168156
Price to Book Ratio 1.53
Return on Assets (%) 6.95
Return on Capital (%) 9.76
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.79
Total Assets 24585.92
Total Liabilities 24585.92
Total Equity 17877.46
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 4.91
Return on Capital (%) 5.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.63
Total Assets 22914.48
Total Liabilities 22914.48
Total Equity 16738.58
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 8.71
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.78
Total Assets 20617.52
Total Liabilities 20617.52
Total Equity 14809.50
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 8.00
Return on Capital (%) 8.95
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 88.25
Total Assets 18951.59
Total Liabilities 18951.59
Total Equity 13226.26
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 7.14
Return on Capital (%) 8.06
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 256.48
Total Assets 17142.69
Total Liabilities 17142.69
Total Equity 11942.08
Share Outstanding 282168156
Price to Book Ratio 1.53
Return on Assets (%) 9.46
Return on Capital (%) 10.76
Particulars MAR 2023 (Values in Cr)
Net Income 868.45
Cash from Operations 1265.93
Cash from Investing -528.49
Cash from Financing -77.45
Net change in Cash 19.44
Free Cash Flow 1873.69
Particulars MAR 2022 (Values in Cr)
Net Income 1441.24
Cash from Operations 1667.09
Cash from Investing -333.28
Cash from Financing -520.49
Net change in Cash 254.88
Free Cash Flow 2457.21
Particulars MAR 2021 (Values in Cr)
Net Income 1382.47
Cash from Operations 1641.45
Cash from Investing -675.23
Cash from Financing -441.77
Net change in Cash 14.19
Free Cash Flow 2416.21
Particulars MAR 2020 (Values in Cr)
Net Income 1096.07
Cash from Operations 1859.36
Cash from Investing -783.51
Cash from Financing -444.66
Net change in Cash 173.99
Free Cash Flow 2791.78
Particulars MAR 2019 (Values in Cr)
Net Income 1300.62
Cash from Operations 1766.80
Cash from Investing -698.99
Cash from Financing -738.73
Net change in Cash -297.07
Free Cash Flow 3006.16
Particulars MAR 2023 (Values in Cr)
Net Income 1571.87
Cash from Operations 1890.48
Cash from Investing -431.46
Cash from Financing -978.49
Net change in Cash 64.09
Free Cash Flow 2080.10
Particulars MAR 2022 (Values in Cr)
Net Income 2337.44
Cash from Operations 1606.78
Cash from Investing -896.92
Cash from Financing -305.12
Net change in Cash 14.02
Free Cash Flow 1770.13
Particulars MAR 2021 (Values in Cr)
Net Income 1943.75
Cash from Operations 1579.25
Cash from Investing -1235.23
Cash from Financing -80.79
Net change in Cash -72.60
Free Cash Flow 1790.72
Particulars MAR 2020 (Values in Cr)
Net Income 1534.64
Cash from Operations 1918.46
Cash from Investing -1607.38
Cash from Financing -139.41
Net change in Cash -167.68
Free Cash Flow 2037.66
Particulars MAR 2019 (Values in Cr)
Net Income 2021.01
Cash from Operations 2888.04
Cash from Investing -2255.60
Cash from Financing -155.10
Net change in Cash 78.87
Free Cash Flow 3132.85
Company Name Price P/E P/B Market Cap 52 Week Low/High
GLENMARK PHARMACEUTICALS 1413.35 0.00 5.08 39883.06 702.05 / 1429.95
BLISS GVS PHARMA LTD 110.15 12.05 1.19 1155.28 77.65 / 148.95
CIPLA LTD 1485.15 28.17 4.49 119928.54 1028.00 / 1581.70
FERMENTA BIOTECH LIMITED 229.35 0.00 2.33 675.00 137.10 / 262.00
GLAXOSMITHKLINE PHARMA LT 2570.70 66.32 24.49 43549.21 1376.50 / 2759.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
GLENMARK PHARMACEUTICALS 1413.35 27.99 1.73 39883.06 702.05 / 1429.95
AMRUTAJAN HEALTH LTD 738.70 47.47 7.40 2135.63 556.05 / 826.00
ASTRAZENECA PHARMA IND LT 6349.65 106.48 22.29 15874.13 3730.00 / 7550.00
BLISS GVS PHARMA LTD 110.15 15.17 1.16 1155.28 77.65 / 148.95
ABBOTT INDIA LIMITED 27407.65 48.49 15.74 58241.26 21907.45 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1406.30
  • 26 Days 1315.30
  • 10 Days 1383.50
  • 50 Days 1232.50
  • 12 Days 1369.90
  • 100 Days 1134.60
  • 20 Days 1338.10
  • 200 Days 810.80
1412.67
PIVOT
First Resistance 1425.68
Second Resistance 1438.02
Third Resistance 1451.03
First Support 1400.33
Second Support 1387.32
Third Support 1374.98
RSI 90.36
MACD 54.63
Commodity Channel Index (CCI) 91.69
ADX 67.72
Williams % R -7.21

Over 1 Month

down

14.34

Over 3 Months

down

37.66

Over 6 Months

down

60.71

Over 1 Year

down

96.21

Over 3 Years

down

27.44

Over 5 Years

down

26.69

GLENMARK PHARMACEUTICALS Future

Future: Price

30 May
1010.35
27 Jun
1018.25
25 Jul
1019.50
25 May
0 100 200 300 400 500 600

Discount/Premium

25 Jul
6.45
29 Aug
10.50
25 May
0 1 2 3 4 5 6 7

Active Calls

1100.0
771
1000.0
629
1060.0
553
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1000.0
804
980.0
217
940.0
143
25 Jul
0 500 1000 1500 2000 2500

GLENMARK PHARMACEUTICALS Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
21.45
Promoter Holdings
46.64
FII
20.98
DII
10.91
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Saldanha Family Trust Shareholding of Promoter and Promoter Group 1.28241936E8 45.45
Hdfc Mutual Fund - Hdfc Mid-cap Opportunities Fund Public Shareholding 1.0250498E7 3.63
Government Pension Fund Global Public Shareholding 9181327.0 3.25
Smallcap World Fund, Inc Public Shareholding 8820014.0 3.13
Ashish Dhawan Public Shareholding 7200000.0 2.55
Ellipsis Partners Llc Public Shareholding 4750000.0 1.68
Aditya Birla Sun Life Trustee Private Limited A/c Public Shareholding 4244779.0 1.5
Blanche Elizabeth Saldanha Shareholding of Promoter and Promoter Group 1114327.0 0.39
Glenn Mario Saldanha Shareholding of Promoter and Promoter Group 989939.0 0.35
Cherylann Maria Pinto Shareholding of Promoter and Promoter Group 758485.0 0.27
Robin Joseph Pinto Shareholding of Promoter and Promoter Group 497500.0 0.18
Neha Saldanha Shareholding of Promoter and Promoter Group 26000.0 0.01

GLENMARK PHARMACEUTICALS

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-09-18 2.5 Final 2023-09-19 Equity shares 2022-09-12 2.5 Final 2022-09-14 Equity shares 2021-09-08 2.5 Final 2021-09-10 Equity shares 2020-09-17 2.5 Final 2020-09-19 Equity shares 2019-09-19 2.0 Final 2019-09-21 Equity shares 2018-09-19 2.0 Final 2018-09-22 Equity shares 2017-09-20 2.0 Final 2017-09-22 Equity shares 2016-08-03 2.0 Final 2016-08-05 Equity shares 2015-09-10 2.0 Final 2015-09-14 Equity shares 2014-07-10 2.0 Final 2014-07-14 Equity shares 2013-07-18 2.0 Final 2013-07-22 Equity shares 2012-07-19 2.0 Final 2012-07-23 Equity shares 2011-07-28 0.4 Final 2011-08-01 Equity shares 2010-09-16 0.4 Final 2010-09-20 Equity shares 2009-09-10 0.4 Final 2009-09-14 Equity shares 2007-11-07 1.4 Interim 2007-11-08 Equity shares 2007-01-04 0.8 Interim 2007-01-05 Equity shares 2005-04-27 0.0 Interim 2005-05-02 Equity shares
Ex-Date Ex-Bonus Ratio
2005-03-08 2005-03-04 1:1
Ex-Date Old FV NEW FV Record Date
2007-09-10 2.0 1.0 2007-09-17 2003-10-23 10.0 2.0 2003-10-31

Learn More About Stocks

About GLENMARK PHARMACEUTICALS

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GLENMARK PHARMACEUTICALS

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

The share price of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1412.95 and for BSE is ₹ 1408.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE is ₹ 3,98,68.95 Cr. and for BSE is ₹ 3,97,29.28 Cr. as of now.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1427.00 and ₹ 715.20 and for BSE is ₹ 1429.95 and ₹ 702.05.

How to Buy Glenmark Pharmaceuticals Ltd share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Glenmark Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 96.21%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300 Cr MTF Book

icon-with-text
loader